// App-Quantinova.ai

PB0206 : Characterisation and Evaluation of a Candidate Bethesda Assay Reference Reagent Developed from Recombinant, Patient-Derived FVIII Inhibitors

Researchers

Presenter

  • C. Coxon

Principal Investigators

  • J. Beavis

  • X. Yu

  • S. Diamond

  • A. Riches

  • S. Raut

Medical Centers

  • National Institute for Biological Standards and Control, Biotherapeutics Group, Potters Bar, Herts, United Kingdom

  • Churchill Hospital, Oxford Haemophilia Centre, Oxford, United Kingdom

  • University of Pennsylvania, Materials Science and Engineering, Philadelphia, United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved